SCHEMBL5109846

SCHEMBL5109846

COC(=O)COc1c(Cl)cccc1Cl

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.65
LMNA P02545 1/20 0.54
PTPN7 P35236 1/20 0.52
PTPN12 Q05209 1/20 0.52
PTPN22 Q9Y2R2 1/20 0.52
KDM4E B2RXH2 1/20 0.50
PTGS2 P35354 1/20 0.47
POLB P06746 2/20 0.45
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
NLRP3 Q96P20 1/20 0.43
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
ACLY P53396 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10410458 0.82 KMT2A (0.61) KMT2ALMNAPTPN7PTPN12PTPN22
SCHEMBL7433745 0.81 LMNA (0.59) KMT2ALMNAKDM4EPTGS2POLB
SCHEMBL22307856 0.81 KMT2A (0.69) KMT2APTPN7PTPN12PTPN22POLB
SCHEMBL8816518 0.81 LMNA (0.58) KMT2ALMNAKDM4EPTGS2ALDH1A1
SCHEMBL7172967 0.80 KMT2A (0.74) KMT2APTPN7PTPN12PTPN22POLB
SCHEMBL5000478 0.80 LMNA (0.62) KMT2ALMNAKDM4EPOLBMAPT
SCHEMBL10428803 0.79 KMT2A (0.57) KMT2ALMNAPOLBALDH1A1GAA
SCHEMBL6815943 0.79 LMNA (0.56) KMT2ALMNAKDM4EPTGS2ALDH1A1
SCHEMBL9505425 0.79 KMT2A (0.71) KMT2APTPN7PTPN12PTPN22POLB
SCHEMBL3729436 0.79 KMT2A (1.00) KMT2ALMNAPTPN7PTPN12PTPN22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117645540-A Preparation method of chlorophenoxycarboxylate 山东润博生物科技有限公司 2024-03-05 CN disclosed
WO-2019179291-A2 PREPARATION METHOD FOR CHLOROPHENOXYCARBOXYLATE 山东润博生物科技有限公司 2019-09-26 WO disclosed
WO-2019179288-A2 PREPARATION METHOD FOR CHLOROPHENOXYCARBOXYLATE 山东润博生物科技有限公司 2019-09-26 WO disclosed
CN-108947820-A Preparation method of chlorinated phenoxy carboxylic ester 山东润博生物科技有限公司 2018-12-07 CN disclosed
CN-108947806-A A kind of preparation method of chlorobenzene oxycarboxylic acid amine salt 山东润博生物科技有限公司 2018-12-07 CN disclosed
CN-108947807-A A kind of preparation method of chlorobenzene oxycarboxylic acid amine salt 山东润博生物科技有限公司 2018-12-07 CN disclosed
CN-108947840-A A kind of preparation method of chlorobenzene oxycarboxylic acid ester 山东润博生物科技有限公司 2018-12-07 CN disclosed
US-7449581-B2 6-Substituted pyrido-pyrimidines POCHE PALO ALTO LLC (US) 2008-11-11 US disclosed
CN-100376571-C 6-substituted pyrido-pyrimidines HOFFMANN LA ROCHE (CH) 2008-03-26 CN disclosed
US-20070135458-A1 6-Substituted pyrido-pyrimidines CHEN JIAN J 2007-06-14 US disclosed
US-7169794-B2 6-substituted pyrido-pyrimidines ROCHE PALO ALTO LLC (US) 2007-01-30 US disclosed
EP-1361880-B1 6-SUBSTITUTED PYRIDO-PYRIMIDINES HOFFMANN LA ROCHE (CH) 2005-09-28 EP disclosed
US-20040116698-A1 6-Substituted pyrido-pyrimidines CHEN JIAN JEFFREY (US) 2004-06-17 US disclosed
CN-1503672-A 6-substituted pyridopyrimidines - 2004-06-09 CN disclosed
US-6696566-B2 SELECTIVE P38 KINASE INHIBITORS RELATIVE TO CYCLIN-DEPENDENT KINASES AND TYROSINE KINASES SYNTEX (U.S.A.) LLC 2004-02-24 US disclosed
EP-1361880-A2 6-SUBSTITUTED PYRIDO-PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-19 EP disclosed
US-20030171584-A1 Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. SYNTEX (U.S.A.) LLC 2003-09-11 US disclosed
WO-2002064594-A2 6-SUBSTITUTED PYRIDO-PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135458-A1 6-Substituted pyrido-pyrimidines P2RX6, P2RX1, P2RX7 KMT2A 2116/4885LMNA 2628/4885PTPN7 2351/4885
US-20030171584-A1 Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. ARRB1, MAPK1, MAPK8 KMT2A 3077/4885LMNA 4583/4885PTPN7 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.